Jean-Marc Chavatte

National Centre for Infectious Diseases

Singapore

SCHOLARLY PAPERS

2

DOWNLOADS

229

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (2)

1.

Antibody Response of Heterologous vs Homologous mRNA Vaccine Boosters Against the SARS-CoV-2 Omicron Variant: Interim Results from the PRIBIVAC Study, A Randomized Clinical Trial

Number of pages: 35 Posted: 16 Mar 2022
National Centre for Infectious Diseases, Duke NUS Medical School, National Centre for Infectious Diseases, National Centre for Infectious Diseases, Agency for Science, Technology and Research (A*STAR) - A*STAR Infectious Diseases Labs, University of Liverpool, University of Liverpool, Duke-NUS Medical School, National Centre for Infectious Diseases, National Centre for Infectious Diseases, National Centre for Infectious Diseases, Singapore, National Centre for Infectious Diseases, Singapore, National Centre for Infectious Diseases, National Centre for Infectious Diseases, National Centre for Infectious Diseases, National Centre for Infectious Diseases, National Centre for Infectious Diseases, Duke-NUS Medical School, University of Liverpool, Agency for Science, Technology and Research (A*STAR) - A*STAR Infectious Diseases Labs, National University of Singapore (NUS), National Centre for Infectious Diseases, Agency for Science, Technology and Research (A*STAR) - A*STAR Infectious Diseases Labs, Nanyang Technological University (NTU) - Lee Kong Chian School of Medicine, Duke-NUS Medical School - Programme in Emerging Infectious Diseases and National Centre for Infectious Diseases, Singapore
Downloads 193 (221,807)

Abstract:

Loading...

COVID-19 vaccine booster, humoral immunity, omicron, live virus neutralization

2.

Comparison of the Clinical Features, Viral Shedding and Immune Response in Vaccine Breakthrough Infection by the Omicron and Delta Variants

Number of pages: 35 Posted: 24 Jun 2022
National University of Singapore (NUS) - National University Hospital, Agency for Science, Technology and Research (A*STAR) - A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR) - A*STAR Infectious Diseases Labs, National University of Singapore (NUS) - Department of Microbiology and Immunology, Agency for Science, Technology and Research (A*STAR) - A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR) - A*STAR Infectious Diseases Labs, National University of Singapore (NUS) - Department of Microbiology and Immunology, National Centre for Infectious Diseases, Singapore, National Centre for Infectious Diseases, National Centre for Infectious Diseases, National Centre for Infectious Diseases, National Centre for Infectious Diseases, Singapore, Agency for Science, Technology and Research (A*STAR) - A*STAR Infectious Diseases Labs, National Centre for Infectious Diseases, Agency for Science, Technology and Research (A*STAR) - A*STAR Infectious Diseases Labs, National University of Singapore (NUS) - Department of Microbiology and Immunology, National University of Singapore (NUS) - Department of Microbiology and Immunology, Nanyang Technological University (NTU) - Lee Kong Chian School of Medicine, Agency for Science, Technology and Research (A*STAR) - A*STAR Infectious Diseases Labs, National Centre for Infectious Diseases, Singapore and Agency for Science, Technology and Research (A*STAR) - A*STAR Infectious Diseases Labs
Downloads 36 (604,038)

Abstract:

Loading...

COVID-19, SARS-CoV-2, Delta, Omicron, variants of concern, vaccine breakthrough